Literature DB >> 25610109

Distribution of HLA Tissue Groups in Patients with Gastric Cancer.

Mehmet Bilici1, Nihat Okcu1, Kerim Cayır1, Ibrahim Pirim2, Salim B Tekin1, Cemal Gundogdu3.   

Abstract

OBJECTIVE: Gastric cancer is an important disease that is seen all over the world and that threats public health. At the same time, gastric cancer is a heterogeneous disorder with multifactorial etiologies. Recent studies have shown a significant association between HLA antigens and gastric adenocarcinoma. The aim of the present study was to determine the distribution of HLA class I (HLA-A, B and C) and class II (HLA-DR, DQ and DP) antigens in Turkish patients with gastric adenocarcinoma.
MATERIALS AND METHODS: HLA alleles or HLA haplotypes associated with gastric cancer were established in the Turkish population using PSR-SSP analysis in 71 unrelated patients with gastric cancer and in 82 unrelated healthy controls. The statistical significance of differences in allele frequencies between patients and controls was measured by the Chi-square test with Yates's correction.
RESULTS: The study revealed that the HLA-Cw5 antigen is more prevalent in patients with gastric cancer (p=0.042) and that the HLA-DRB1*15 antigen is more prevelent in the control group (p=0.021).
CONCLUSION: It is probable that HLA-Cw5 is a risk factor for gastric cancer whereas HLA-DRB1*15 plays a protective role for this disease. The results show that different loci on HLA may control resistance to or tendency for any disease in different societies; each society should determine its own tissue group.

Entities:  

Keywords:  Gastric cancer; HLA antigens; HLA-Cw5; HLA-DRB1*15

Year:  2010        PMID: 25610109      PMCID: PMC4261300          DOI: 10.5152/eajm.2010.03

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN: 1308-8734


  18 in total

Review 1.  Genetic susceptibility and gastric cancer risk.

Authors:  Carlos A González; Núria Sala; Gabriel Capellá
Journal:  Int J Cancer       Date:  2002-07-20       Impact factor: 7.396

2.  The epidemiology of gastric cancer.

Authors:  P Correa
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

3.  HLA and disease association: the case of gastric cancer.

Authors:  B Rigas
Journal:  Gastroenterology       Date:  1996-08       Impact factor: 22.682

4.  DNA typing of HLA class I (HLA-A) and class II genes (HLA-DR, -DQ and -DP) in Japanese patients with gastric cancer.

Authors:  M Ohmori; S Yasunaga; Y Maehara; K Sugimachi; T Sasazuki
Journal:  Tissue Antigens       Date:  1997-09

5.  HLA-DQA1 and -DQB1 genes and Helicobacter pylori infection in Italian patients with gastric adenocarcinoma.

Authors:  F Perri; A Piepoli; M Quitadamo; M Quarticelli; A Merla; M Bisceglia
Journal:  Tissue Antigens       Date:  2002-01

6.  Gastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori.

Authors:  H Enroth; I Eriksson; M Held; O Nyrén; L Engstrand; L E Hansson; U B Gyllensten
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

7.  Survival and the HL-A system in acute lymphoblastic leukaemia.

Authors:  S D Lawler; P T Klouda; P G Smith; M M Till; R M Hardisty
Journal:  Br Med J       Date:  1974-03-23

8.  Association of the HLA-DRB1 gene locus with gastric adenocarcinoma in Japan.

Authors:  M Ohtani; T Azuma; S Yamazaki; A Yamakawa; Y Ito; A Muramatsu; M Dojo; Y Yamazaki; M Kuriyama
Journal:  Dig Liver Dis       Date:  2003-07       Impact factor: 4.088

9.  Lack of an association between carcinoma of the stomach and the major histocompatibility complex (HLA) in Cape Coloureds.

Authors:  R W Martell; P J van Eeden; M V Madden; E D du Toit; D M Dent
Journal:  Tissue Antigens       Date:  1988-09

10.  HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.

Authors:  Jun Lin; Chang-Sheng Deng; Jie Sun; Xian-Gong Zheng; Xing Huang; Yan Zhou; Ping Xiong; Ya-Ping Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.